Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

• Christian Winther Eskelund,
• Alexandra Albertsson-Lindblad,
• Arne Kolstad,
• Anna Laurell,
• Riikka Räty,
• Lone Bredo Pedersen,
• Christian Hartmann Geisler,
• Mats Jerkeman,
• Kirsten Grønbæk

Affiliations

Christian Winther Eskelund

Department of Hematology, Rigshospitalet, Copenhagen, Denmark;Biotech Research and Innovation Centre, Copenhagen, Denmark

Alexandra Albertsson-Lindblad

Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Oncology and Pathology, Sweden

Arne Kolstad

Department of Oncology, Oslo University Hospital, Norway

Anna Laurell

Department of Oncology, Uppsala University Hospital, Sweden

Riikka Räty

Department of Hematology, Helsinki University Hospital, Finland

Lone Bredo Pedersen

Department of Hematology, Rigshospitalet, Copenhagen, Denmark

Christian Hartmann Geisler

Department of Hematology, Rigshospitalet, Copenhagen, Denmark

Mats Jerkeman

Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Oncology and Pathology, Sweden

Kirsten Grønbæk

Department of Hematology, Rigshospitalet, Copenhagen, Denmark;Biotech Research and Innovation Centre, Copenhagen, Denmark